FDA Grants Priority Review to Tovorafenib in Pediatric Relapsed/Progressive Low-Grade Glioma

The FDA has granted priority review to a new drug application seeking the approval of tovorafenib monotherapy for the treatment of pediatric patients with relapsed or progressive low-grade glioma.

Related Keywords

Jeremy Bender , ,Response Assessment ,Prescription Drug User Fee Act ,Day One Biopharmaceuticals ,Pediatric Neuro Oncology ,Low Grade Glioma ,Pediatric Low Grade Glioma ,Fda ,Priority Review ,Tovorafenib ,